IGF-1: Evidence-Based Ways to Improve This Number

What IGF-1 Actually Measures

IGF-1 is a single-chain polypeptide produced mainly by hepatocytes in response to growth hormone binding its receptor. Unlike GH itself, which pulses erratically throughout the day, IGF-1 circulates at relatively stable concentrations bound to IGF-binding proteins (primarily IGFBP-3). That stability makes it the preferred biomarker for assessing the GH-IGF axis in clinical practice.

The Endocrine Society's 2011 clinical practice guideline on GH deficiency recommends serum IGF-1 as the initial screening test when GH deficiency is suspected, noting that a level below the age-adjusted reference range has high specificity for adult GH deficiency [1]. Reference ranges shift significantly across the lifespan. Adolescents during peak puberty may have IGF-1 values above 500 ng/mL, while adults over 60 often fall between 70 and 190 ng/mL. Context matters more than the raw number.

IGF-1 also serves as a monitoring tool during GH replacement or peptide therapy. The AACE 2019 guidelines for growth hormone use in adults state that dose titration should target an IGF-1 level "in the middle of the age-adjusted normal range," checking levels every 4 to 8 weeks until stable [2]. Interpreting your result without knowing your age-specific reference interval leads to unnecessary concern or false reassurance.

Why a Low IGF-1 Matters

A persistently low IGF-1 signals that the GH-IGF axis is underperforming. The clinical consequences go beyond stature. Adults with GH deficiency and low IGF-1 show increased visceral adiposity, reduced lean mass, decreased bone mineral density, impaired lipid profiles, and lower quality-of-life scores compared to matched controls [3].

In a meta-analysis of 12 randomized controlled trials (N=573) published in the Journal of Clinical Endocrinology & Metabolism, GH replacement in GH-deficient adults reduced total body fat by a mean of 2.56 kg and increased lean body mass by 2.69 kg over 6 to 12 months of therapy [3]. These body-composition shifts correlated with the degree of IGF-1 normalization.

Low IGF-1 also appears in non-GH-deficient contexts. Caloric restriction, chronic illness, uncontrolled type 1 diabetes, liver cirrhosis, and hypothyroidism all suppress hepatic IGF-1 output. Identifying and treating the underlying cause is the first step before considering GH-axis interventions.

Dietary Strategies That Raise IGF-1

Protein intake is the single strongest dietary determinant of circulating IGF-1. A cross-sectional analysis from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (N=4,731) found that each 10 g/day increase in animal protein intake was associated with a 2.5% higher serum IGF-1 concentration [4]. Dairy protein showed the most consistent association across studies.

The mechanism is straightforward. Amino acids (particularly leucine and arginine) stimulate hepatic IGF-1 gene transcription both directly and through GH-receptor upregulation. A diet providing 1.2 to 1.6 g of protein per kilogram of body weight per day appears sufficient to optimize IGF-1 in otherwise healthy adults [5].

Specific dietary considerations:

• Dairy intake. Milk consumption raises IGF-1 more than equivalent protein from plant sources. A randomized crossover trial in 204 older adults showed that 3 daily servings of milk increased IGF-1 by 10% over 12 weeks compared to a non-dairy control period [6].
• Caloric adequacy. Chronic energy deficit suppresses IGF-1 regardless of macronutrient composition. In one study of female athletes with low energy availability, IGF-1 was 36% lower than in energy-replete controls [7].
• Zinc status. Zinc is a cofactor for GH receptor signaling. A placebo-controlled trial in zinc-deficient children showed that 3 months of zinc supplementation (20 mg/day elemental zinc) raised IGF-1 by 26% [8].

Eating enough total calories and enough protein is the foundation. Micronutrient repletion (zinc, vitamin D, magnesium) is second-line but still relevant if deficiencies are documented.

Exercise Protocols That Boost the GH-IGF Axis

Resistance training produces the most reliable exercise-induced GH release, which translates to higher IGF-1 over time. A 2010 systematic review in Sports Medicine concluded that high-volume, moderate-to-high-intensity resistance training (3 to 4 sets of 8 to 12 reps at 70 to 85% of 1-rep max) produces the largest acute GH responses [9].

The downstream effect on IGF-1 is measurable but takes weeks. In a 12-week study of untrained adults performing progressive resistance training 3 days per week, resting IGF-1 increased by 20% from baseline, with the change correlating with gains in lean mass (r=0.44, P<0.01) [10].

High-intensity interval training (HIIT) also triggers GH pulses. A small RCT (N=28) comparing 8 weeks of HIIT versus moderate continuous cycling found that HIIT increased IGF-1 by 15.2% versus 4.8% in the moderate group [11]. The difference was statistically significant.

Practical takeaways for IGF-1 optimization:

• Perform compound resistance exercises (squat, deadlift, bench press, row) 3 to 4 times per week.
• Use moderate-to-heavy loads with rest periods of 60 to 90 seconds between sets.
• Add 1 to 2 HIIT sessions per week (20 to 30 minutes).
• Avoid chronic overtraining, which suppresses the GH-IGF axis through cortisol elevation and energy deficit.

Sleep: The Dominant GH Pulse Window

Approximately 70% of daily GH secretion occurs during slow-wave sleep (stages N3), concentrated in the first sleep cycle [12]. Sleep deprivation or fragmentation directly reduces both GH pulse amplitude and 24-hour IGF-1 levels.

A landmark study by Van Cauter et al. published in JAMA demonstrated that restricting sleep to 4 hours per night for 6 nights reduced IGF-1 by approximately 20% in healthy young men and shifted their hormonal profile toward a pattern resembling biological aging [12]. Recovery sleep restored levels within 48 to 72 hours.

Dr. Eve Van Cauter noted in describing her findings: "Sleep debt has a harmful impact on carbohydrate metabolism and endocrine function. The effects are similar to those seen in normal aging and therefore sleep debt may increase the severity of age-related chronic disorders" [12].

Actionable sleep hygiene for GH-IGF optimization:

• Target 7 to 9 hours of sleep per night consistently.
• Prioritize the first 90 minutes of sleep onset (where the largest GH pulse occurs) by keeping a consistent bedtime.
• Avoid alcohol within 3 hours of bedtime, as it suppresses slow-wave sleep.
• Treat obstructive sleep apnea if present, since intermittent hypoxia blunts GH secretion.

GH-Secretagogue Peptide Therapy

When lifestyle optimization alone does not normalize IGF-1, GH-secretagogue peptides offer a pharmacologic option that stimulates the body's own GH production rather than injecting exogenous GH directly. Several peptides have clinical data supporting their ability to raise IGF-1.

Tesamorelin is the only FDA-approved GH-releasing hormone (GHRH) analog. It was approved for HIV-associated lipodystrophy based on Phase III data showing a mean IGF-1 increase of 81 ng/mL (approximately 30 to 40% from baseline) with 2 mg subcutaneous daily dosing over 26 weeks [13]. The FDA label for Egrifta notes that IGF-1 should be monitored during treatment and that the dose should be reduced or discontinued if IGF-1 exceeds the upper limit of the age-adjusted normal range [14].

Sermorelin (GHRH 1-29) was previously FDA-approved for pediatric GH deficiency and is now used off-label in adults. In a study of 118 GH-deficient adults treated with sermorelin 1 mg subcutaneous at bedtime, IGF-1 rose by a mean of 22% at 12 weeks, with improvements in body composition and sleep quality [15].

CJC-1295 combined with ipamorelin is a commonly prescribed peptide combination that pairs a GHRH analog (CJC-1295) with a ghrelin-mimetic GH secretagogue (ipamorelin). Published data is more limited than for tesamorelin, but observational cohort data suggest IGF-1 increases of 15 to 30% with standard dosing protocols (100 to 300 mcg of each, subcutaneous, 5 nights per week) [16].

The Endocrine Society's position on GH secretagogues emphasizes that IGF-1 monitoring every 4 to 8 weeks during titration is mandatory, with the goal of keeping IGF-1 within the upper half of the age-adjusted normal range [1].

When and How to Lower IGF-1

Not everyone wants to raise IGF-1. Elevated levels are associated with increased risk of certain cancers. A pooled analysis of prospective studies (N=3,609 cases, 5,765 controls) found that individuals in the highest quartile of circulating IGF-1 had a 40% higher risk of colorectal cancer compared with those in the lowest quartile (OR 1.40, 95% CI 1.16 to 1.68) [17].

The relationship between IGF-1 and longevity is nuanced. Animal models consistently show that reduced GH-IGF signaling extends lifespan. The Laron syndrome cohort in Ecuador (individuals with GH receptor mutations and very low IGF-1) shows near-complete absence of cancer and diabetes despite obesity, as documented by Guevara-Aguirre et al. in Science Translational Medicine [18]. Dr. Valter Longo, who collaborated on this research, stated: "The individuals with Laron syndrome had very low rates of cancer and diabetes, providing direct human evidence that reduced GH-IGF-1 signaling can protect against age-related disease" [18].

Evidence-based approaches to lower IGF-1:

• Caloric restriction. A 2-year controlled trial (CALERIE, N=218) of 25% caloric restriction reduced IGF-1 by 21% compared to the ad libitum control group [19].
• Protein moderation. Reducing protein intake to 0.8 g/kg/day (the RDA minimum) reliably lowers IGF-1 by 10 to 15% within weeks [4].
• Plant-based dietary patterns. Vegans have approximately 13% lower IGF-1 levels than omnivores after adjustment for BMI and caloric intake [20].
• Intermittent fasting. Alternate-day fasting protocols reduce IGF-1 by 20 to 30% in short-term studies (4 to 8 weeks) [21].

The clinical decision to lower IGF-1 should be individualized. Reducing IGF-1 in someone with already-low levels risks accelerating sarcopenia, osteoporosis, and metabolic dysfunction. Lab values always exist in the context of the whole patient.

Supplements and Micronutrients

Several micronutrients modulate the GH-IGF axis, though the effect sizes are smaller than those of macronutrient and lifestyle interventions.

Vitamin D. Observational data from NHANES (N=3,592) showed a positive linear association between 25-hydroxyvitamin D and IGF-1 levels across the entire range of vitamin D status [22]. Supplementing to achieve 25(OH)D levels above 30 ng/mL may support IGF-1 production, though randomized trial data specifically targeting IGF-1 as a primary endpoint are limited.

Magnesium. Magnesium is required for IGF-1 receptor phosphorylation. In the InCHIANTI cohort study (N=1,453 adults aged 65+), serum magnesium was positively associated with IGF-1 after multivariate adjustment (P<0.001) [23].

Arginine. Intravenous arginine is used as a GH provocation test in clinical endocrinology. Oral arginine (5 to 9 g before bed) may produce a modest GH spike, but evidence for sustained IGF-1 elevation is weak [24]. It remains more useful as a diagnostic agent than a therapeutic one.

Melatonin. Low-dose melatonin (0.5 to 3 mg at bedtime) may indirectly support IGF-1 by improving slow-wave sleep duration. A small RCT (N=30) of 3 mg melatonin nightly for 6 months showed a 12% increase in IGF-1 in perimenopausal women, though this finding needs replication [25].

Monitoring and Interpretation

IGF-1 should be drawn fasting in the morning for consistency. It does not require the same timing precision as cortisol, but overnight fasting reduces interference from postprandial insulin surges that acutely modulate IGF-binding protein levels.

Repeat testing every 8 to 12 weeks during an active optimization protocol is reasonable. Expect changes to lag 4 to 6 weeks behind the intervention that caused them, since IGF-1 reflects cumulative GH exposure over weeks, not hours.

According to the AACE/ACE 2019 growth hormone guidelines, "IGF-1 should be measured using a reliable assay with established age- and sex-specific normative data, and results should be interpreted in the context of nutritional status, liver function, and thyroid status" [2]. A low IGF-1 in a patient with uncontrolled hypothyroidism or hepatic dysfunction does not automatically indicate GH deficiency.

Clinical red flags that warrant endocrinology referral include IGF-1 persistently above the 97th percentile for age (screen for acromegaly) or below the 3rd percentile despite adequate nutrition and sleep (evaluate for structural pituitary disease with a GH stimulation test).